TScan Therapeutics
proprietary pipeline addresses liquid and solid tumors | TScan Therapeutics
Company
Deck Type
IPO
Sector
Industry
Deck date
July 2021
Slide
9 of 43
Related slides by other companies
Erasca
Investor Presentation
August 2023
pan could address unmet needs in approximately patients in the us and total | Erasca
Alkermes
Investor Day
March 2021
alkermes design approach build functional in the tumor through engineered tumor targeted subunits key design considerations and challenges split to create functionally inactive subunits to be directed to the tumor engineer subunits to address inherent stability challenges in production and enhance the affinity of non linked and subunits identify unique tumor targeting antigen and generate proprietary antibodies certain proteins exhibit increased expression in tumors relative to normal tissue and can be leveraged to target to tumors with high specificity produce novel engineered tumor targeted fusion proteins using proprietary antibodies subunits can be fused to proprietary antibody against unique tumor antigen fusion protein engineering non targeted engineered inactive subunit tumor targeting antibody tumor targeted subunits | Alkermes
Erasca
Investor Presentation
November 2023
pan could address unmet needs in approximately patients in the us and total | Erasca
Erasca
Investor Presentation
August 2023
eras and eras i could address unmet needs in over patients in the us and it i syne | Erasca
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights